Abstract
Clinical positron emission tomography (PET) is a molecular imaging method that has recently emerged from being a research tool to a mainstream imaging modality. PET uses a glucose analogue (fluoro-2-deoxy-D-glucose or FDG) tagged with a positron-emitting isotope (radioactive fluorine or 18F), to produce 18F-FDG. 18F-FDG follows the metabolic pathway of glucose throughout the body, with rapid and increased selective uptake in: • pathological tissues (particularly tumours) • inflammatory cells (e.g. granulocytes, macrophages). Whereas other radiopharmaceutical agents usually pass dynamically through the body, 18F-FDG is trapped in these particular cells, allowing the ‘annihilation radiation’ emanating from these sites to be detected. This contribution will discuss the current status of PET imaging in oncology and cardiology.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
